A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder
March 03, 2017
Steven Potkin, MD
UC Irvine Medical Center in Orange, CA
The purpose of this research study is to help understand how well experimental rapastinel works to treat major depressive disorder (MDD). "Experimental" means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). We will look at how well it can treat symptoms of a major depressive episode while a person is on a stable dose of another antidepressant therapy (ADT). We will also look at any side effects which may occur with rapastinel when in actual use.
You are eligible to participate in this study if you:
- Are between 18 and 65 years of age
- Have a diagnosis of major depressive disorder
- Are willing to undergo all study procedures at the study center over the study period
It is expected that your study participation may last over a period of approximately 4 to 6 weeks, with 11 to 12 study visits. You may need to attend unscheduled visits for safety or other reasons.
You may or may not receive any direct medical benefit from participating in this study. Your participation in the study may benefit others with your disease or condition as a result of the knowledge gained from this research.
Total compensation for completing the study as a subject is up to $750 over the study period.
Ioana Popica, Clinical Research Coordinator